Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP insider Greg Keenan sold 8,305 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $8.23, for a total value of $68,350.15. Following the sale, the insider now owns 153,484 shares of the company's stock, valued at $1,263,173.32. The trade was a 5.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Greg Keenan also recently made the following trade(s):
- On Monday, March 3rd, Greg Keenan sold 12,239 shares of Aurinia Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total transaction of $97,912.00.
Aurinia Pharmaceuticals Trading Up 0.2 %
NASDAQ AUPH traded up $0.02 on Tuesday, reaching $8.19. 1,014,566 shares of the company were exchanged, compared to its average volume of 1,472,463. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The business's fifty day moving average price is $8.06 and its 200 day moving average price is $7.90. The stock has a market capitalization of $1.12 billion, a P/E ratio of -53.96 and a beta of 1.26. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.67.
Wall Street Analyst Weigh In
Separately, StockNews.com downgraded shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Wednesday, February 19th.
Check Out Our Latest Report on Aurinia Pharmaceuticals
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the company. Tang Capital Management LLC raised its stake in Aurinia Pharmaceuticals by 16.6% during the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company's stock worth $75,697,000 after purchasing an additional 1,200,000 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $9,662,000. Point72 Asset Management L.P. purchased a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at approximately $7,630,000. Lazard Asset Management LLC lifted its holdings in Aurinia Pharmaceuticals by 341.9% in the fourth quarter. Lazard Asset Management LLC now owns 596,389 shares of the biotechnology company's stock valued at $5,355,000 after acquiring an additional 461,430 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in Aurinia Pharmaceuticals in the third quarter worth approximately $3,330,000. Institutional investors and hedge funds own 36.83% of the company's stock.
About Aurinia Pharmaceuticals
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
See Also
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
